269 related articles for article (PubMed ID: 16676402)
1. Gene expression in poorly differentiated papillary thyroid carcinomas.
Fluge Ø; Bruland O; Akslen LA; Lillehaug JR; Varhaug JE
Thyroid; 2006 Feb; 16(2):161-75. PubMed ID: 16676402
[TBL] [Abstract][Full Text] [Related]
2. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.
Wasenius VM; Hemmer S; Kettunen E; Knuutila S; Franssila K; Joensuu H
Clin Cancer Res; 2003 Jan; 9(1):68-75. PubMed ID: 12538453
[TBL] [Abstract][Full Text] [Related]
4. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
5. NATH, a novel gene overexpressed in papillary thyroid carcinomas.
Fluge Ø; Bruland O; Akslen LA; Varhaug JE; Lillehaug JR
Oncogene; 2002 Aug; 21(33):5056-68. PubMed ID: 12140756
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
7. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases.
Asioli S; Erickson LA; Sebo TJ; Zhang J; Jin L; Thompson GB; Lloyd RV
Am J Surg Pathol; 2010 Jan; 34(1):44-52. PubMed ID: 19956062
[TBL] [Abstract][Full Text] [Related]
8. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
[TBL] [Abstract][Full Text] [Related]
9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
11. CITED1 protein expression suggests Papillary Thyroid Carcinoma in high throughput tissue microarray-based study.
Prasad ML; Pellegata NS; Kloos RT; Barbacioru C; Huang Y; de la Chapelle A
Thyroid; 2004 Mar; 14(3):169-75. PubMed ID: 15072698
[TBL] [Abstract][Full Text] [Related]
12. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z
Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043
[TBL] [Abstract][Full Text] [Related]
15. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
16. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas.
Liu RT; Huang CC; You HL; Chou FF; Hu CC; Chao FP; Chen CM; Cheng JT
Oncogene; 2002 Jul; 21(31):4830-7. PubMed ID: 12101421
[TBL] [Abstract][Full Text] [Related]
18. SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.
Moraitis D; Karanikou M; Liakou C; Dimas K; Tzimas G; Tseleni-Balafouta S; Patsouris E; Rassidakis GZ; Kouvaraki MA
Surgery; 2014 Dec; 156(6):1542-8; discussion 1548-9. PubMed ID: 25456951
[TBL] [Abstract][Full Text] [Related]
19. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
[TBL] [Abstract][Full Text] [Related]
20. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation.
Franzoni A; Dima M; D'Agostino M; Puppin C; Fabbro D; Loreto CD; Pandolfi M; Puxeddu E; Moretti S; Celano M; Bruno R; Filetti S; Russo D; Damante G
Thyroid; 2009 Mar; 19(3):247-55. PubMed ID: 19207009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
